{"meshTagsMajor":["Molecular Targeted Therapy"],"meshTags":["Angiogenesis Inhibitors","Antibodies, Monoclonal, Humanized","Antineoplastic Agents","Colorectal Neoplasms","Digestive System Neoplasms","Gastrointestinal Stromal Tumors","Humans","Liver Neoplasms","Molecular Targeted Therapy","Pancreatic Neoplasms","Receptor, Epidermal Growth Factor","Stomach Neoplasms"],"meshMinor":["Angiogenesis Inhibitors","Antibodies, Monoclonal, Humanized","Antineoplastic Agents","Colorectal Neoplasms","Digestive System Neoplasms","Gastrointestinal Stromal Tumors","Humans","Liver Neoplasms","Pancreatic Neoplasms","Receptor, Epidermal Growth Factor","Stomach Neoplasms"],"publicationTypes":["English Abstract","Journal Article","Review"],"abstract":"Targeted therapies have an increasing importance in digestive oncology. These new treatments have been authorized in colon cancer, gastric cancer, pancreatic cancer, endocrine cancer and gastrointestinal stromal tumors. The oncologist should develop high abilities to use these therapies especially concerning the indications, response\u0027s biomarkers, toxicities and evaluation methods.","title":"[Targeted therapies in digestive oncology].","pubmedId":"22743093"}